Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Open-label, Randomized, Two-arm Pilot Study to Investigate the Toxicity and Pharmacokinetics of 2-Weekly and 3-Weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer.

NCT03343977 is registered in ClinicalTrials.gov with Peng Wang, MD PhD as lead sponsor.

NCT NCT03343977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03343977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Open-label, Randomized, Two-arm Pilot Study to Investigate the Toxicity and Pharmacokinetics of 2-Weekly and 3-Weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer.
Lead sponsor
Peng Wang, MD PhD
Phase
Phase 1/2
Overall status
Withdrawn
Start date
February 14, 2018
Completion date
April 30, 2029
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer